Supplementary Table 6.
Antimicrobial susceptibility profiles of Citrobacter spp., Serratia spp., Morganella spp., and Proteus spp. from blood in mainland China during the period 2004–2014
| Antibiotics | Citrobacter spp. (n = 22) | Serratia spp. (n = 86) | Morganella spp. (n = 22) | Proteus spp. (n = 30) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC50 | MIC90 | S | R | MIC50 | MIC90 | S | R | MIC50 | MIC90 | S | R | MIC50 | MIC90 | S | R | |
| Amoxicillin | >256 | >256 | 0.0 | 100.0 | 64 | >256 | 10.0 | 90.0 | 256 | >256 | 0.0 | 100.0 | >256 | >256 | 14.3 | 85.7 |
| AMC | 64 | 128 | 33.3 | 66.7 | 64 | 128 | 20.0 | 80.0 | 128 | 256 | 0.0 | 100.0 | 4 | 8 | 85.7 | 0.0 |
| Piperacillin | 256 | >256 | 22.7 | 63.6 | 4 | 256 | 74.4 | 23.3 | 2 | 128 | 77.3 | 13.6 | 2 | 64 | 75.0 | 3.6 |
| TZP | 4 | 256 | 77.3 | 13.6 | 2 | 8 | 96.5 | 3.5 | 0.25 | 0.5 | 100.0 | 0.0 | 0.5 | 1 | 100.0 | 0.0 |
| Mezlocillin | 256 | >256 | 29.4 | 58.8 | 8 | >256 | 74.1 | 21.0 | 4 | 128 | 73.7 | 21.1 | 8 | 128 | 54.2 | 25.0 |
| MSU | 64 | 128 | 41.2 | 17.6 | 4 | 64 | 79.0 | 12.3 | 2 | 16 | 100.0 | 0.0 | 4 | 8 | 100.0 | 0.0 |
| Cefazolin | >256 | >256 | 9.1 | 90.9 | >256 | >256 | 2.3 | 97.7 | 256 | >256 | 0.0 | 90.9 | 128 | >256 | 21.4 | 64.3 |
| Cefuroxime | 128 | >256 | 27.3 | 72.7 | 256 | >256 | 3.5 | 96.5 | 32 | 128 | 27.3 | 59.1 | 256 | >256 | 35.7 | 64.3 |
| Ceftriaxone | 128 | >256 | 30.0 | 70.0 | 0.5 | 128 | 69.0 | 28.6 | 0.016 | 2 | 75.0 | 25.0 | 1 | 256 | 45.8 | 54.2 |
| Cefotaxime | 64 | 256 | 31.8 | 68.2 | 0.5 | 128 | 70.9 | 27.9 | 0.031 | 8 | 77.3 | 9.1 | 4 | >256 | 50.0 | 46.4 |
| Ceftazidime | 32 | 128 | 40.9 | 59.1 | 0.25 | 8 | 88.4 | 4.7 | 0.125 | 16 | 77.3 | 13.6 | 0.062 | 32 | 82.1 | 14.3 |
| Cefoperazone | 64 | >256 | 40.9 | 54.5 | 2 | 256 | 76.7 | 22.1 | 1 | 32 | 77.3 | 4.5 | 4 | 128 | 60.7 | 35.7 |
| CSL | 16 | 32 | 63.6 | 18.2 | 1 | 32 | 88.4 | 5.8 | 1 | 4 | 100.0 | 0.0 | 1 | 4 | 96.4 | 0.0 |
| Cefepime | 0.25 | 8 | 54.5 | 31.8 | 0.125 | 16 | 76.7 | 16.3 | 0.031 | 0.062 | 100.0 | 0.0 | 1 | 16 | 64.3 | 14.3 |
| Aztreonam | 16 | 256 | 35.3 | 58.8 | 0.125 | 64 | 72.8 | 19.8 | 0.016 | 0.5 | 100.0 | 0.0 | 0.5 | 8 | 87.5 | 8.3 |
| Moxalactam | 0.5 | 4 | 72.7 | 13.6 | 0.5 | 4 | 93.0 | 4.7 | 0.125 | 0.125 | 100.0 | 0.0 | 0.125 | 0.25 | 100.0 | 0.0 |
| Imipenem | 0.125 | 0.5 | 90.9 | 9.1 | 0.5 | 1 | 90.7 | 7.0 | 2 | 4 | 40.9 | 22.7 | 1 | 2 | 64.3 | 7.1 |
| Meropenem | 0.031 | 0.062 | 88.2 | 11.8 | 0.062 | 0.25 | 93.8 | 6.2 | 0.062 | 0.125 | 100.0 | 0.0 | 0.062 | 0.125 | 100.0 | 0.0 |
| Panipenem | 0.125 | 0.5 | 90.0 | 10.0 | 0.5 | 2 | 88.1 | 8.3 | 1 | 2 | 65.0 | 10.0 | 1 | 2 | 79.2 | 4.2 |
| Ertapenem | 0.062 | 0.25 | 88.2 | 11.8 | 0.031 | 0.25 | 92.6 | 6.2 | 0.016 | 0.031 | 100.0 | 0.0 | 0.016 | 0.031 | 100.0 | 0.0 |
| Gentamycin | 1 | 2 | 71.4 | 23.8 | 1 | 128 | 77.9 | 17.4 | 0.5 | 128 | 54.5 | 27.3 | 8 | >256 | 46.4 | 39.3 |
| Amikacin | 1 | 2 | 95.5 | 4.5 | 2 | 128 | 81.4 | 17.4 | 1 | 4 | 100.0 | 0.0 | 4 | >256 | 85.7 | 14.3 |
| Tetracycline | 2 | 256 | 58.8 | 29.4 | 32 | 128 | 22.2 | 64.2 | 32 | 64 | 36.8 | 47.4 | 32 | 64 | 4.2 | 91.7 |
| Tigecycline | 0.25 | 1 | 100.0 | 0.0 | 2 | 4 | 87.7 | 0.0 | 2 | 8 | 57.9 | 15.8 | 2 | 4 | 62.5 | 8.3 |
| Ciprofloxacin | 0.125 | 1 | 68.2 | 31.8 | 0.125 | 4 | 87.2 | 8.1 | 0.5 | 8 | 81.8 | 13.6 | 4 | 64 | 39.3 | 60.7 |
| Levofloxacin | 0.5 | 16 | 68.2 | 27.3 | 0.25 | 4 | 86.0 | 8.1 | 1 | 2 | 90.9 | 9.1 | 4 | 32 | 39.3 | 46.4 |
| Nitrofurantoin | 32 | 128 | 52.9 | 17.6 | 256 | >256 | 33.3 | 65.4 | 64 | 128 | 5.3 | 42.1 | 128 | 128 | 4.2 | 58.3 |
| Fosfomycin | 0.25 | 0.25 | 100.0 | 0.0 | 8 | 32 | 75.3 | 23.5 | 256 | >256 | 26.3 | 57.9 | 8 | 256 | 66.7 | 29.2 |
| Polymyxin B | 2 | 4 | 81.8 | 18.2 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
| Colistin | 2 | 2 | 100.0 | 0.0 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
ND: No detection; AMC: Amoxicillin-clavulanic acid; TZP: Piperacillin-tazobactam; MSU: Mezlocillin-sulbactam; CSL: Cefoperazone-sulbactam; MIC: Minimum inhibitory concentration; R: Resistance rate (%); S: Susceptibility rate (%).